Tirofiban
As of the edition of 20 October 2026, Tirofiban is a small molecule: marketed, first approved in 1998 (US); acts on ITGA2B; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1999
- Kind
- Small molecule
- Brand name
- Aggrastat
- First approved
- 14 May 1998 (US)
- Approvals on record
- 8 in 4 regions
- Holder of the most recent approval
- Medicure; 3 holders in all
- Registered trials
- 50, 6 stopped early
- Disease areas
- Heart and blood vessels; Nervous system; Hormones; Infections; Lungs and airways; Nutrition and metabolism
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route B because of this drug.
Companies on route B for this drug
In the product3 companies are on route B because of Tirofiban.
See the 3 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ITGA2B | Integrin alpha-IIb | P08514 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 0 | 2 | 2 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 7 | 4 | 1 | 1 |
| Phase 3 | 18 | 5 | 8 | 2 |
| Phase 4 | 18 | 8 | 3 | 1 |
| All trials | 50 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Earlier holder | 1998 to now |
| Cipher Pharmaceuticals | Applicant | 1999 to now |
| Medicure | Acquired holder and Lead sponsor of trials | 2006 to now |